Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in the following upcoming investor conferences:

Wedbush PacGrow Healthcare ConferenceFormat: Management will participate in investor meetings Date: Tuesday, August 8, 2023Location: New York, NY

Canaccord Genuity 43rd Annual Growth ConferenceFormat: Presentation.Date: Wednesday, August 9, 2023Time: 10:00 a.m. ETLocation: Boston, MA

A live webcast of the presentation will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia and our preclinical pipeline, including programs in amyotrophic lateral sclerosis and Huntington’s disease. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:Stuart HendersonPassage Bio267.866.0114[email protected]

Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare Communications312.961.2502[email protected]

You May Also Be Interested In

• Bang & Olufsen appoints new executive leadership team
• Sampo Group’s results for January–June 2026
• First six months 2026 interim report: sustained strategic progress and consistent financial performance. Full-year 2026 guidance for Adjusted EBITDA and Investments reiterated